Minerva Neurosciences announces results of dose escalation study evaluating roluperidone
Minerva Neurosciences announced the results from a prospective, double-blind, placebo-controlled, randomized single-escalating dose study in healthy subjects to evaluate the investigational drug roluperidone as monotherapy administered at nine ascending doses. November 19, 2018